logo
Post readers react to elite's aim to create ‘super-babies'

Post readers react to elite's aim to create ‘super-babies'

Washington Post4 days ago
Technology Post readers react to elite's aim to create 'super-babies'
'I'm torn,' one reader said. 'Having a child which would never develop a terrible disease ... would be wonderful. However, a little like playing god.'
(Camille Cohen/For The Washington Post)
By Michael Blackmon
and Alexandra Pannoni
July 19, 2025 at 7:00 a.m. EDT
Just now
1 min
Post reporters Elizabeth Dwoskin and Yeganeh Torbati published a must-read article detailing how Silicon Valley elites, including Elon Musk, are using novel gene technology to produce 'super-babies.'
The article set off a lively discussion in the comments section, where readers of various ages and perspectives sounded off.
Eager to hear more, we published a callout asking readers how far they would go to ensure a healthy baby and added a similar query to the prompt of the original article. We received more than a thousand responses.
Here are some of the best reader reactions, which have been lightly edited for length and clarity and are printed with permission.
Jessica Orlando,
37
Los Angeles
' I am coming at this question from a different perspective, having gone through IVF to combat infertility, and we now have an amazing son who is 19 months old. Our journey was different from many in that we went through four rounds of egg retrievals and embryo selections, but none made our doctor's cut for transplantation based on genetic testing given that the ones that made it each had what were considered genetic abnormalities. I personally reached my end point of doing more retrievals so we decided to transfer two abnormal embryos, asking our doctor to use the best quality that were available, and one of them grew into our son. He's wonderful and perfect in our eyes — no health issues or abnormalities and has an amazing personality and disposition. If we had followed our doctor's advice, he wouldn't exist today. '
Maggie Cooper,
43
Arlington, Virginia
' I am a carrier for cystic fibrosis (and have a mild form of the disease that presents in my lungs/sinuses), so my husband did genetic testing to see if he also was a carrier. While CF is not quite the early death sentence it used to be, it was not something we felt comfortable knowingly passing to a child. Thankfully he was not a carrier. Nine years ago, while I was pregnant with our first daughter, my husband was diagnosed with Stage 3 oligodendroglioma — a rare brain cancer. He had brain surgery and underwent radiation and chemo and, while there is no remission for this type of cancer, he has had no recurrence. He was adamant that we not have another child until his doctors could determine if his cancer was hereditary. After participating in natural history studies at NIH for many years, his doctors felt very confident that his cancer was not linked to genetics. We had our second daughter (via IVF) in summer 2023. '
Brenda Feeney,
79
Leesburg, Virginia
' I'm torn. Having a child which would never develop a terrible disease (Parkinson's, MS, etc.) would be wonderful. However, a little like playing god. Only the wealthy will be able to do this, so is their gene pool better than the rest of our? Most of the wealthy individuals we must endure today are cruel, vile and inhumane. Do we want more of these people? '
Paul Ojanen,
61
Duluth, Minnesota
' If you narrow selection over time, no matter what, you select for other unknown traits. As usual they are applying their very narrow field ... algorithms and computability ... to a process that needs randomness for long-term success. Eventually they'll succeed in what they want, a 'purebred' lineage, but with all types of unforeseen problems, just like purebred dogs. '
(Camille Cohen/For The Washington Post)
Jann Becker,
70
St. Louis
' We chose to adopt in part because I have bipolar disorder and substance abuse, both of which run in my father's family, that I didn't wish to pass on. Choosing to bear only the embryo(s) without a known problem is, to me, the most ethical choice for people who know there's a hereditary disease in their family that would seriously impact a future child's life. If all the women in a given generation used that process for a disease like, say, Huntington's, could be eliminated for that family — but that means all of those women would need to accept their own test results and undergo an invasive medical procedure before becoming pregnant. '
Anca Vlasopolos,
76
Centerville, Massachusetts
' These extraordinarily ignorant people know nothing about genetics and the bell curve. Geniuses do not have genius children. People on the lower IQ scale may have a very intelligent child. But the white-supremacy myth driving these attempts is merely what it is=racism. '
Justin Wilson,
36
Silver Spring, Maryland
' I love it! Knew the idea/process would eventually become a thing. It's concerning that so many of you think this is bad. Is it just envy? Irrational fear of technology? Something that could lead to a healthier population is undeniably a good thing in my book. '
Judy Pelowski,
66
Red Oak, Texas
' At my age, I'm not having any babies. However, I believe there's something to be said for natural selection. They've said for years that mongrel dogs are healthier than purebreds. … Are you really going to eliminate anyone who doesn't have a high enough intelligence level or might one day die? What if, during their lifespan, the low-intelligence individual can see things others can't or has strength the others don't have and saves someone? What if the unhealthy child is a genius? Who's going to do all the work that the designer babies can't do? Testing for terrible deformities or diseases that would not allow the child to make it more than a short time after birth, and only in a very pained way, yes. Testing that saves a person a life of pain, yes. Vanity testing? Are you sure you want to go that way? '
Chris Strohbeck,
67
Reston, Virginia
' I find it ironic that these so-called risk takers are so obsessed with eliminating any and all risk, whether perceived or not, whether scientifically supported or not. I am not in their age cohort, but it occurs to me that one of the most concerning aspects of advanced technology (AI topping the list) accelerated by young adults is that these entrepreneurs don't have enough perspective. It's not always true that age comes with wisdom, but time spent living a life does broaden your experience base, sharpen your decision-making, and develop your moral thinking. '
Francesca A.,
78
Oakland, California
' I became pregnant in 1986 after six years of trying various methods because of infertility. Because of my infertility, I was advised to wait and have an amnio rather than have a chorionic villus sampler test due to the risk of aborting the fetus in the latter test. Well, it turned out that my amniocentesis revealed our baby had the Trisomy 18 defect. Would pre-pregnancy genetic testing have indicated this as a possible risk? Obviously, in our case, finances would've been a factor, but I would never want to have to go through a late-term therapeutic abortion at almost 7 months again. '
Mary Redmond,
62
Philadelphia
' Prospective parents are 'rolling the dice,' like it or not. That's axiomatic from a genuinely scientific (Darwinian) perspective. These experts are con artists who add to the uncertainty. An old-fashioned fortune teller or astrologer might provide more 'value.' '
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings
Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings

Yahoo

time26 minutes ago

  • Yahoo

Top Analyst Calls UnitedHealth a 'Top Pick' Ahead of Earnings

July 22 - UnitedHealth Group (NYSE:UNH) has tumbled roughly 42% year?to?date, driven by rising Medicare Advantage costs, a surprise CEO exit, withdrawn guidance and a Department of Justice probe. However, ahead of its July 29 Q2 earnings, Bernstein analyst Lance Wilkes tapped UNH as a 'Top Pick,' saying the pullback creates an attractive entry point. He noted the stock trades at about 13.5 times forward earnings, below its ten?year average. Warning! GuruFocus has detected 4 Warning Sign with UNH. Wilkes cut his 2025 EPS estimate by 10% to reflect reserve strengthening and cost pressures in individual and Medicaid segments, plus a cleanup of OptumHealth risk contracts. Yet he projects earnings per share could double by 2029, implying a 19% compound annual growth rate. The analyst expects cost normalization to begin in Medicaid in Q3 and in Medicare Advantage in early 2026 as utilization patterns stabilize. He also highlighted a hardening pricing environment for government managed?care plans as a margin tailwind. Is UNH Stock a Buy? Based on the one year price targets offered by 24 analysts, the average target price for UnitedHealth Group Inc is $375.46 with a high estimate of $677.00 and a low estimate of $270.00. The average target implies a upside of +33.08% from the current price of $282.14. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025
Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025

Yahoo

time26 minutes ago

  • Yahoo

Sleep Number Corporation to Announce Second Quarter 2025 Results on July 30, 2025

MINNEAPOLIS, July 22, 2025--(BUSINESS WIRE)--Sleep Number Corporation (Nasdaq: SNBR) will release its fiscal second quarter results through June 28, 2025, before market open on Wednesday, July 30, 2025. Management will host its regularly scheduled conference call to discuss the company's results at 8:30 a.m. EDT (7:30 a.m. CDT; 5:30 a.m. PDT). To access the webcast, please visit the investor relations area of the Sleep Number website at The webcast replay will remain available for approximately 60 days. About Sleep Number Corporation Sleep Number is a sleep wellness company. We are guided by our purpose to improve the health and wellbeing of society through higher quality sleep. To date, our innovations have improved nearly 16 million lives. Our sleep wellness platform helps solve sleep problems, whether it's providing individualized temperature control for each sleeper through our Climate360 smart bed or applying our 34 billion hours of longitudinal sleep data and expertise to research with global institutions. Our smart bed ecosystem helps people sleep better by offering adjustable comfort and personalized sleep and health insights. Millions of Smart Sleepers benefit from higher quality sleep, and our 3,400 dedicated team members are passionate about creating innovative solutions through our vertically integrated business model, including direct-to-consumer selling in 630 stores and online. To learn more about life-changing, individualized sleep, visit a Sleep Number® store near you, our newsroom and investor relations sites, or View source version on Contacts Investor Contact investorrelations@ Media Contact Muriel Lussier, Sleep Number Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

Yahoo

time26 minutes ago

  • Yahoo

Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

– Video webcast now available on-demand SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ('Senti Bio'), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Senti Bio Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company's wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti's Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships. Availability of Other Information About Senti Biosciences, Inc. For more information, please visit the Senti Bio website at or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website ( including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store